qualitative immunochromatographic dipstick test for detecting the presence of phosphorylated IGFBP-1 in cervical secretions during pregnancy. - India CDSCO Medical Device Registration
qualitative immunochromatographic dipstick test for detecting the presence of phosphorylated IGFBP-1 in cervical secretions during pregnancy. is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2018/000214_32b1f06d1df8d5163d1dc0da97a3cd89_e7048edc8ed2077e68ed95e4d24762e3. This device is marketed under the brand name insulin-like growth factor binding protein-1. The license holder is Bharat Serums And Vaccines Limited, and it is classified as Device Class Class B. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.
Brand Name
insulin-like growth factor binding protein-1
License Holder
Bharat Serums And Vaccines LimitedDevice Class
Approving Authority
CDSCO
Product Information
Actim® Partus test is a visually interpreted, qualitative immunochromatographic dipstick test for detecting the presence of phosphorylated IGFBP-1 (insulin-like growth factor binding protein-1) in cervical secretions during pregnancy. The test is intended for professional use to help predict the risk of preterm or imminent delivery when fetal membranes are intact.
